# Are your MRI contrast agents cost-effective? Learn more about generic Gadolinium-Based Contrast Agents.





This information is current as of April 18, 2024.

# <sup>99m</sup>Tc-Bicisate and <sup>99m</sup>Tc-HMPAO SPECT Imaging in Early Spontaneous Reperfusion of Cerebral Embolism

Kuniaki Ogasawara, Kazuo Mizoi, Satoru Fujiwara and Takashi Yoshimoto

*AJNR Am J Neuroradiol* 1999, 20 (4) 626-628 http://www.ajnr.org/content/20/4/626

# <sup>99m</sup>Tc-Bicisate and <sup>99m</sup>Tc-HMPAO SPECT Imaging in Early Spontaneous Reperfusion of Cerebral Embolism

Kuniaki Ogasawara, Kazuo Mizoi, Satoru Fujiwara, and Takashi Yoshimoto

Summary: Two patients with a cerebral embolism were evaluated by using both <sup>99m</sup>Tc-ethyl cysteinate dimer (ECD, or Bicisate) and <sup>99m</sup>Tc-hexamethylpropyleneamine oxime (HMPAO) single-photon emission computed tomography (SPECT). In one patient, <sup>99m</sup>Tc-ECD SPECT images revealed hypoactivity in a reflow hyperemic area where an infarct was seen later on CT scans. In another patient, a reperfused area showed hyperactivity on <sup>99m</sup>Tc-ECD SPECT without any abnormality on follow-up CT. <sup>99m</sup>Tc-ECD represents a potential agent with which to evaluate cerebral tissue viability in early reperfusion after ischemia.

Technetium-99m-labeled ethyl cysteinate dimer (ECD, or Bicisate) has been developed as a brain perfusion tracer for use with single-photon emission computed tomography (SPECT) (1). Early studies have shown that the distribution of <sup>99m</sup>Tc-ECD in the brain correlated with regional brain perfusion in healthy volunteers and in patients with chronic strokes (2-6). These investigators have also reported that <sup>99m</sup>Tc-ECD SPECT imaging failed to show reflow hyperemia and underestimated the flow abnormality in patients with subacute strokes as compared with <sup>99m</sup>Tc-hexamethylpropyleneamine oxime (HMPAO), N-isopropyl-p-[<sup>123</sup>I] iodoamphetamine (<sup>123</sup>I-IMP), and xenon-133 studies (4–6). To our knowledge, <sup>99m</sup>Tc-ECD SPECT imaging of reflow hyperemia within 24 hours after the onset of stroke has not yet been reported.

In this article, we describe two patients with early spontaneous reperfusion in cerebral embolism by comparing <sup>99m</sup>Tc-ECD SPECT with <sup>99m</sup>Tc-HMPAO SPECT imaging.

## **Case Reports**

#### Case 1

Left-sided hemiparesis developed suddenly in a 54-year-old man with atrial fibrillation. A CT study of the brain 4 hours after onset of symptoms revealed no responsible lesion. <sup>99m</sup>Tc-HMPAO SPECT at 4.5 hours showed hypoactivity in the right

frontal and temporal lobes (Fig 1A). Cerebral angiography revealed an embolic occlusion of the terminal portion of the right internal carotid artery. The patient was treated with steroids. Neither intraarterial nor intravenous thrombolytic therapy was used.

Follow-up SPECT was performed 12 hours after the initial study. The first part of the follow-up study was begun 5 minutes after injection of 800 MBq of <sup>99m</sup>Tc-HMPAO and lasted 20 minutes. Immediately after the end of the <sup>99m</sup>Tc-HMPAO study, 950 MBq of <sup>99m</sup>Tc-ECD was injected. Five minutes later, the second SPECT study was carried out for 20 minutes. After reconstruction, the tomographic images from the first study were subtracted from the images of the second study, and the time differences in data acquisition were corrected to obtain <sup>99m</sup>Tc-ECD SPECT images. <sup>99m</sup>Tc-HMPAO and <sup>99m</sup>Tc-ECD SPECT images were produced independently by this subtraction technique.

Both sets of SPECT images depicted hypoactivity in the right frontal lobe. The <sup>99m</sup>Tc-HMPAO SPECT scans showed hyperactivity in the right temporal lobe, and the <sup>99m</sup>Tc-ECD SPECT scans showed hypoactivity in the same area (Fig 1B). Although a CT scan obtained after the SPECT study revealed a partial infarct in the right frontal lobe, low-density areas had not yet developed in the right temporal lobe (Fig 1C), and subsequent cerebral angiography showed partial recanalization of the lower trunk of the right middle cerebral artery (MCA). However, 10 hours later, the patient's motor functions rapidly deteriorated and a CT scan showed a partially hemorrhagic infarct in this area (Fig 1D).

#### Case 2

A 69-year-old man with atrial fibrillation was admitted with sudden onset of left hemiparesis. <sup>99m</sup>Tc-HMPAO SPECT was performed 7.5 hours after the onset of the symptoms and showed hypoactivity in the right parietal lobe (Fig 2A). Cerebral angiography showed an embolic occlusion of the central artery of the right MCA. Without intraarterial or intravenous thrombolytic therapy, his left hemiparesis resolved completely 10 hours after the onset of symptoms.

Twelve hours after the initial SPECT study, we obtained <sup>99m</sup>Tc-HMPAO and <sup>99m</sup>Tc-ECD SPECT images using the same procedure as described for case 1. Both SPECT studies depicted hyperactivity in the right parietal lobe (Fig 2B). Subsequent cerebral angiography showed complete recanalization of the right MCA. A follow-up CT scan did not show any abnormality in the hyperactive area (Fig 2C).

### Discussion

Follow-up <sup>99m</sup>Tc-HMPAO SPECT images obtained 12 hours after the initial study in our two patients showed focal hyperactivity indicative of reflow hyperemia. This reflow phenomenon is considered to be evidence of recanalization of occluded vessels due to spontaneous thrombolysis. Patients with embolic stroke often have reflow caused

Received June 19, 1998; accepted after revision November 11. From the Department of Neurosurgery, Kohnan Hospital (K.O., S.F.), and the Department of Neurosurgery, Tohoku University School of Medicine (K.M., T.Y.), Japan.

Address reprint requests to Kuniaki Ogasawara, MD, Department of Neurosurgery, Iwate Medical University, 19–1, Uchimaru, Morioka 020–8505, Japan.

<sup>©</sup> American Society of Neuroradiology




FIG 1. Case 1: 54-year-old man with atrial fibrillation and sudden onset of left-sided hemiparesis.

A, <sup>99m</sup>Tc-HMPAO SPECT image 4.5 hours after the onset of stroke shows hypoactivity in the right frontal and temporal lobes.

B, 99mTc-HMPAO SPECT image (*left*) obtained 12 hours after the initial study shows hyperactivity in the right temporal lobe; a 99mTc-ECD SPECT image (*right*) shows hypoactivity in the same area.

C, and D, CT scans after the SPECT study reveal a low-density area only in the right frontal lobe (C); 10 hours later, a partially hemorrhagic infarct has developed in the right temporal lobe (D).


by early spontaneous thrombolysis in the acute stage.

<sup>99m</sup>Tc-ECD is metabolized rapidly in the brain by a specific enzymatic pathway to a polar complex that is trapped in the brain (7). Because of this retention mechanism of <sup>99m</sup>Tc-ECD, hypofixation in reflow hyperemic areas in patients with subacute stroke may be due to either slow or absent deesterification caused by ischemic brain damage (4-6). In case 1, <sup>99m</sup>Tc-ECD SPECT images revealed hypoactivity in the reflow hyperemic area, whereas the CT scan obtained immediately after the SPECT study did not show low density. At follow-up CT 10 hours later, however, a partially hemorrhagic infarct had developed in this area of reflow hyperemia. This suggests that 99mTc-ECD SPECT may be able to predict whether an infarct will develop in patients with early reperfusion in ischemia before low density appears on CT scans. On the other hand, the findings in case 2 suggest that <sup>99m</sup>Tc-ECD SPECT may be able to depict focal hyperperfusion

in areas without brain damage not only in focal seizures but also in reflow hyperemia, as Nakagawara et al (6) demonstrated in a patient with subacute stroke.

## Conclusion

Although our observations are limited to two patients, they suggest that <sup>99m</sup>Tc-ECD is a potential agent with which to evaluate cerebral tissue viability in early reperfusion of ischemia. Additional studies are required to confirm these findings and speculations; however, the characteristics of <sup>99m</sup>Tc-ECD may be suitable for assessing the effects of fibrinolytic therapy using urokinase or tissue plasminogen activator in cerebral embolism, since these conditions often show signs of reflow hyperemia when therapy is successful. The greatest problem of fibrinolytic therapy has been reported to be hemorrhagic transformation, which may occur by early recanalization within a few hours after the








Fig 2. Case 2: 69-year-old man with atrial fibrillation and sudden onset of left-sided hemiparesis.

A, <sup>gen</sup>Tc-HMPAO SPECT image 7.5 hours after the onset of stroke shows hypoactivity in the right parietal lobe.

*B*, Both <sup>99m</sup>Tc-HMPAO (*left*) and <sup>99m</sup>Tc-ECD (*right*) SPECT images obtained 12 hours after the initial study depict hyperactivity in the right parietal lobe.

C, Follow-up CT scan does not show any abnormality.

insult in some patients and result in rapid deterioration of the patient's neurologic condition (8). Because reflow hyperemia in the nonviable neuronal tissue is considered to increase the risk of hemorrhagic transformation, <sup>99m</sup>Tc-ECD SPECT studies performed early after successful fibrinolytic therapy may predict neurologic exacerbation.

#### References

- Cheesman EH, Blanchette MA, Ganey MV, Maheu LJ, Miller SJ, Watson AD. Technetium-99m ECD: ester-derivatized diaminedithiol Tc complexes for imaging brain perfusion. J Nucl Med 1988;29:788
- Leveille J, Botez MI, Taillefer R, Gagnon A, Douesnard JM, Lefebvre B. A clinical comparison of Tc-99m HMPAO and Tc-99m ethyl cysteinate dimer (ECD) in normal volunteers and patients as a brain perfusion imaging agent. J Nucl Med 1988; 29:844
- Devous MD, Leroy RF, Payne JK, Lorimer MK, Bonte FJ. Comparison of Tc-99m ECD to Xe-133 in the SPECT determina-

tion of regional cerebral blood flow in patients with mild perfusion abnormalities. *J Nucl Med* 1990;31:817

- Shishido F, Uemura K, Murakami M, et al. Cerebral uptake of <sup>99m</sup>Tc-Bicisate in patients with cerebrovascular disease in com- parison with CBF and CMRO2 measured by positron emission tomography. J Cereb Blood Flow Metab 1994;14(Suppl 1):S66–S75
- 5. Lassen NA, Sperling B. <sup>99m</sup>Tc-Bicisate reliably images CBF in chronic brain diseases but fails to show reflow hyperemia in subacute stroke: report of a multicenter trial of 105 cases comparing 133Xe and <sup>99m</sup>Tc-Bicisate (ECD, Neurolite) measured by SPECT on the same day. J Cereb Blood Flow Metab 1994; 14(Suppl 1):S44–S48
- Nakagawara J, Nakamura J, Takeda R, et al. Assessment of postischemic reperfusion and diamox activation test in stroke using <sup>99m</sup>Tc-ECD SPECT. J Cereb Blood Flow Metab 1994; 14(Suppl 1):S49–S57
- Walovitch RC, Cheesman EH, Maheu LJ, Hall KM. Studies of the retention mechanism of the brain perfusion imaging agent <sup>99m</sup>Tc- bicisate (<sup>99m</sup>Tc-ECD). J Cereb Blood Flow Metab 1994; 14(Suppl 1):S4–S11
- Overgaard K, Pedersen H, Knudsen JB, Boysen G. Fatal ischemic brain edema after unsuccessful thrombolysis. *Neurol Res* 1990; 12:81–82